Figure S2 from Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
posted on 2023-04-04, 02:20authored byLaure Maneix, Polina Iakova, Shannon E. Moree, Joanne I. Hsu, Ragini M. Mistry, Fabio Stossi, Premal Lulla, Zheng Sun, Ergun Sahin, Sarvari V. Yellapragada, André Catic
Proteasome inhibition down-regulates cell cycle and mitochondrial gene expression in three different MM cell lines.
Funding
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HHS | NIH | National Institute of General Medical Sciences (NIGMS)
Cancer Prevention and Research Institute of Texas (CPRIT)
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
HHS | NIH | National Institute on Aging (NIA)
HHS | NIH | National Cancer Institute (NCI)
HHS | NIH | Office of Research Infrastructure Programs, National Institutes of Health (ORIP)
HHS | NIH | National Center for Research Resources (NCRR)
HHS | NIH | National Institute of Environmental Health Sciences (NIEHS)
History
ARTICLE ABSTRACT
Integrative genomics reveals that a key function of proteasome inhibitors involves limiting the activity of MYC and MYC-dependent genes through epigenetic repression.